Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accumulated Depreciation (2016 - 2024)

Historic Accumulated Depreciation for Celldex Therapeutics (CLDX) over the last 14 years, with Q4 2024 value amounting to $23.5 million.

  • Celldex Therapeutics' Accumulated Depreciation rose 482.02% to $23.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.5 million, marking a year-over-year increase of 482.02%. This contributed to the annual value of $23.5 million for FY2024, which is 482.02% up from last year.
  • According to the latest figures from Q4 2024, Celldex Therapeutics' Accumulated Depreciation is $23.5 million, which was up 482.02% from $22.4 million recorded in Q4 2023.
  • Over the past 5 years, Celldex Therapeutics' Accumulated Depreciation peaked at $23.5 million during Q4 2024, and registered a low of $21.1 million during Q4 2021.
  • For the 5-year period, Celldex Therapeutics' Accumulated Depreciation averaged around $22.0 million, with its median value being $21.6 million (2022).
  • As far as peak fluctuations go, Celldex Therapeutics' Accumulated Depreciation plummeted by 2522.97% in 2020, and later surged by 482.02% in 2024.
  • Celldex Therapeutics' Accumulated Depreciation (Quarter) stood at $21.2 million in 2020, then fell by 0.52% to $21.1 million in 2021, then increased by 2.37% to $21.6 million in 2022, then grew by 3.51% to $22.4 million in 2023, then rose by 4.82% to $23.5 million in 2024.
  • Its Accumulated Depreciation stands at $23.5 million for Q4 2024, versus $22.4 million for Q4 2023 and $21.6 million for Q4 2022.